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Objective: To design, develop, and evaluate an evidence-based decision aid (DA) for patients 
with an asymptomatic abdominal aortic aneurysm (AAA) to inform them about the pros and 
cons of their treatment options (ie, surgery or watchful observation) and to help them make a 
shared decision.
Methods: A multidisciplinary team deﬁ  ned criteria for the desired DA as to design, medical 
content and functionality, particularly for elderly users. Development was according to the 
international standard (IPDAS). Fifteen patients with an AAA, who were either treated or not 
yet treated, evaluated the tool.
Results: A DA was developed to offer information about the disease, the risks and beneﬁ  ts of 
surgical treatment and watchful observation, and the individual possibilities and threats based 
on the patient’s aneurysm diameter and risk proﬁ  le. The DA was improved and judged favor-
ably by physicians and patients.
Conclusion: This evidence-based DA for AAA patients, developed according to IPDAS criteria, 
is likely to be a simple, user-friendly tool to offer patients evidence-based information about the 
pros and cons of treatment options for AAA, to improve patients’ understanding of the disease 
and treatment options, and may support decision making based on individual values.
Keywords: decision support techniques, research design, program development, abdominal 
aortic aneurysm, decision making
Introduction
A decision aid (DA) is a tool to outline treatment options, to explore patient prefer-
ences and values, and to help patients in shared decision making. Such DAs have 
been developed over the years for a wide range of (mainly malignant) conditions as 
an adjunct to physicians’ counseling. Its ultimate goal is to facilitate shared decision 
making and to increase quality of patient care (Molenaar et al 2001; Ruland 2004; 
Whelan et al 2004; Holmes-Rover et al 2005). DAs comprise visual, graphic, or 
video-assisted illustrations of the risks and beneﬁ  ts involved. DAs were found to 
perform better in terms of decreasing decisional conﬂ  ict related to feeling informed, 
increasing knowledge and realistic expectations, increasing active participation 
in preference-sensitive decision making, and reducing the proportion of patients 
who remained undecided post intervention (O’Connor et al 2003; Timmermans 
et al 2004).
An aneurysm of the abdominal aorta (AAA) is a local dilatation of the main 
abdominal artery which can be relatively small or huge. Approximately 75% of these 
AAAs are asymptomatic and are found coincidentally during physical examination 
or by ultrasonography or CT scanning (Lin and Lumsden 2003). The prevalence is 
estimated to range between 1.7% and 6% in the elderly, primarily male, population Patient Preference and Adherence 2008:2 316
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(Drury et al 2005). Patients with an AAA may never suffer 
from it, yet only 20% of them will survive an unexpected 
rupture of their aneurysm.
Surgery of an AAA should prevent rupture of the aneu-
rysm, but may also induce complications and premature 
death due to the very procedure. Key issues in decision-
making are the size of the aneurysm, which is related to risk 
of aneurysm rupture, and the risk of surgical complications 
as a result of advanced age or serious (cardiovascular) 
comorbidity (Lovegrove et al 2008). Hence, patients with 
small aneurysms (5.5 cm in diameter) are considered not 
to require surgery, but are usually managed by means of 
watchful observation with regular ultrasonography (UKSAT 
2002). For larger aneurysms, surgery is commonly advised 
and applied if the risk of complications is considered 
acceptable.
As the disorder per se does not necessarily lead to dis-
ease, the treating vascular surgeon and the patient face the 
dilemma of weighing the risk of rupture of the AAA during 
watchful observation against the risk of complications of 
surgery. As there is no single preferred treatment for these 
patients, their treatment preference plays a crucial role in the 
ﬁ  nal decision to arrive at ‘shared decision-making’ (Charles 
et al 1999). Whenever such preference-sensitive decisions 
are to be made, decision-supportive interventions appear to 
be useful to help patients make an informed choice and to 
standardize the information given.
The aim of this project was to design and develop a DA 
for patients with an asymptomatic AAA to supply patients 
with information as to the pros and cons of the various treat-
ment options, presented in a structured and easily accessible 
manner, eventually to facilitate well-informed and satisfac-
tory decision making.
Methods
The DA was designed at the Academic Medical Center, 
Amsterdam, The Netherlands. Because this study focused on 
the development of a DA, and no intervention was performed 
that might inﬂ  uence the treatment of patients with an AAA, 
approval of the Hospital Ethics Advisory Board was waived. 
No commercial sponsoring was obtained.
The development of the DA was planned in ﬁ  ve stages: 
1) composing a multidisciplinary development and advi-
sory team, 2) deﬁ  ning the requirements of the desired DA, 
3) obtaining the available evidence on the natural history, 
treatment, and complications of AAA, 4) designing and creat-
ing the DA, and ﬁ  nally 5) testing, adjusting, and evaluating 
the DA.
Stage 1: Multidisciplinary 
development team
A multidisciplinary team was assembled, consisting of 
physicians, vascular surgeons, clinical psychologists, patient 
education and computer experts, and former and actual AAA 
patients, who contributed to the development and pilot-
evaluation of the DA.
Stage 2: Content and functional 
requirements
The development was commenced by formulating minimal 
requirements (by DTU, AG, SM). The desired DA should 
match the following criteria:
•  It should be simple to use, read, and understand by elderly 
patients
•  It should be readily available in a format usable both at 
home and the (outpatient) clinic
•  It should contain essential information about the disorder 
itself.
•  It should explain the surgical (open and endovascular) 
and watchful waiting treatment options, their possible 
beneﬁ  ts and disadvantages, and address the known as 
well as unknown aspects as to the prognosis after the 
different treatment options.
•  It should inform patients about their risk level and its 
consequences, ie, mortality and (major) morbidity in 
relation to the anticipated (non) surgical procedure.
•  This information should be presented in an interactive 
mode to guide the patient primarily along the information 
and options relevant to his or her particular condition and 
risk level.
•  Its content should be in accordance with legal standards 
and in agreement with the quality criteria for patient 
decision support technologies as developed by the Inter-
national Patient Decision Aids Standards Collaboration 
(IPDAS) (Elwyn et al 2006).
•  It should provide (references to) the best available, up-
to-date evidence from the medical literature to underpin 
the information given about all treatment options.
Stage 3: Included evidence
Data on rupture risk and beneﬁ  cial or harmful treatment 
effects were based on evidence from the literature searched 
from major medical databases (by AMK), such as PubMed 
and the Cochrane Library up to March 1, 2008. Accuracy of 
data extraction was checked by our group of vascular sur-
geons. From these data, overall estimates of survival, risks, Patient Preference and Adherence 2008:2 317
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and complications for the various treatment options were 
derived to be incorporated in the DA (Greenhalgh et al 2004; 
UKSAT 1998; DREAM 2005;  Baas et al 2008).
The indication for and prognosis after the various treat-
ment options is known to be inﬂ  uenced by the comorbidity 
of the patient (Hirsch et al 2006). A history of renal insuf-
ﬁ  ciency and vascular comorbidity increases the risk of 
postoperative complications in AAA patients. To quantify 
this risk, the Glasgow Aneurysm Score (GAS) has been 
developed, which is a risk score calculated from the patient’s 
age, kidney function, and history of cerebrovascular disease 
(Biancari et al 2003, 2008). This GAS is now a commonly 
used and validated prediction rule to help surgeons in deci-
sion making in AAA patients (Hirzalla et al 2006).
Stage 4: Format, design, and creation 
of the DA
Considering the high age and possible ignorance regard-
ing the use of computers of the DA’s target patients, we 
contemplated whether the optimum DA should be in a 
written or digital form. We initially aimed at producing a 
DA that would provide information tailored to the patient’s 
condition and that would also allow us to record the parts 
of information that would be accessed and appreciated most 
by the patients. We therefore opted for a digital format for 
the DA, in which these data could be automatically recorded 
into log ﬁ  les. Moreover, several graphical images could be 
included to depict the risks and beneﬁ  ts involved in the dif-
ferent treatment options. Although it has been shown that 
graphical presentation of numerical data helps understanding 
such risks (Stiggelbout et al 1997), a wide range of graphical 
presentation forms is available, but it is still unclear which 
one is most effective to convey the information and which 
of these patients prefer most.
The choice for a digital DA entailed designing a user-
friendly, mouse-driven application, in which the patient 
would be guided through simple clicks along a preferential 
information route tailored to the patient’s clinical situation. 
This situation would be determined by the patient’s GAS 
and aneurysm diameter, to be entered at the beginning of 
the DA. If desired, however, the patient should be able to 
access the information regarding any of the other treatment 
options.
Stage 5: DA testing and evaluation
The pilot version of the DA was tested by four vascular 
surgeons, mainly for its medical content, and by four elderly 
subjects, for its usefulness and user-friendliness.
Based on their suggestions, the pilot version of the DA 
was improved and presented to a group of 15 former and 
actual AAA patients to evaluate comprehensibility and user-
friendliness more formally. These patients were invited via 
the Dutch Society of Vascular Patients. A patient sample was 
composed varying in age, gender, computer proﬁ  ciency, edu-
cation level, place of residence, and previous AAA treatment. 
They received the DA via email or were visited personally 
by the investigator (AMK), and were asked to ﬁ  ll in a short 
questionnaire about the DA (Table 2).
Results
Starting April 2007, the pilot version was designed as a 
Powerpoint presentation (Microsoft Ofﬁ  ce 2003; Microsoft 
Corp., Redmond, WA). This comprised a total of 170 pages 
(‘slides’) and offers general information as to the disorder, 
the possible treatment options, and the opportunity to balance 
the risks involved.
Users can thumb through the DA and choose information 
tailored to their individual physical condition. For this purpose, 
action buttons on ‘crossroads’ pages enable to skip the next 
pages on topics the users consider less relevant. In addition, the 
user can be directed to information pertinent to the patient by 
choosing their aneurysm diameter (less than or above 5.5 cm), 
possible treatment options (open or endovascular aneurysm 
repair or watchful observation) as suggested by their surgeon 
or the patient’s personal GAS score. To prevent from ‘getting 
lost’ in the program, a ‘breadcrumb trail’ was added to indicate 
the progress of, and position in, the program. To further com-
ply with the IPDAS criteria, we added the following items: date 
of last update, a statement the developers of the DA would not 
beneﬁ  t from whichever choice the patient would make based 
on the DA, and references to the (level of) evidence for the 
various bits of information given in the DA. In addition we 
elaborated the section in which patients can consider their own 
situation as to treatment options, risks and anxiety. The ﬁ  nal 
pilot version of the DA, developed during a period of three 
months, complied with 33 out of 40 IPDAS criteria.
Some of the pages in the DA are presented in Figures 1–4. 
They illustrate the information supplied on the disease itself 
(Figure 1), the risk of rupture presented as a Figure (the user 
can choose to get verbal explanations as well; Figure 2), the 
various graphical representations of the beneﬁ  ts and risks 
of the endovascular therapy (Figure 3), and a summarizing 
comparison of the pros and cons of surgery versus watchful 
waiting, including an interactive part where patients can ﬁ  ll 
in their personal anxiety or reluctance regarding a certain 
treatment option (Figure 4).Patient Preference and Adherence 2008:2 318
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AAA
An ‘Aortic Abdominal Aneurysm’ (abbreviated as ‘AAA’) is a disorder characterized by a local 
widening of the aortic wall. The normal abdominal aorta has a diameter of about 2 cms. 
An widening of the aorta of more than 3 cms, or more than 1.5 times its original diameter, 
is called an aneurysm. 
Slowly wider
The widening of the aorta is a gradual process. The growth rate may vary, but is usually a 
few millimetres per year.
Continue
5
start
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Normal 
aorta
Aorta with a 
large aneurysm
Figure 1 Sample page from the decision aid illustrating the pathologic anatomy of the abdominal aortic aneurysm.
The figure shows the risk of a rupture (tear) of the aneurysm in the next year.
You can read your personal risk from the figure. 
This risk increases considerably when the aneurysm grows to more than 5 cms in diameter. 
If you click the speaker icon, the figure is explained verbally. 
(Switch on your computer loudspeaker).
Continue
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Click on the speaker for a 
spoken explanation of the figure
Figure 2 Sample page in the decision aid depicting the risk of rupture in relation to the aneurysm diameter. Additional spoken information is provided by clicking the speaker 
button.Patient Preference and Adherence 2008:2 319
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Outcome of endovascular surgery (via the groin)
In this figure you see the possible outcomes in a group of 1000 patients treated for their aneurysm:
Click on the speaker for a spoken explanation of the figure
Click onthe blue button to read which complications
you may suffer from due to the operation
1000 patients
treated
686 patients have
no complications
175 patients have
mild complications
69 patients have
serious complications
70 patients
die from the operation
930 patients
survive the operation
40
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Back
Outcome of endovascular surgery (via the groin)
This bar chart shows the possible outcomes of the operation:
Click on the speaker for a spoken explanation of the figure
Click on the blue button to read which complications
you may suffer from due to the operation
0
10
20
30
40
50
60
70
80
90
100
%
Death
Serious complications
Mild complications
No complications
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Back
Outcome of endovascular surgery (via the groin)
This illustration shows 1000 figurines. Each represents one operated patient.
Red: Death
Orange: Serious complications
Yellow: Mild complications
Neutral: No complicaties 
Click on the speaker for a spoken explanation of the figure
Click on the blue button to read which complications
you may suffer from due to the operation
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Outcome of endovascular surgery (via the groin)
Below you see the complication risks of surgery, expressed as percentages:
Harm
% 7
Serious complication due to surgery:                             7%
Mild complications due to surgery:                               18%
Benefit
No complications from surgery:                                     68%
Click on the speaker for a spoken explanation of the figure
Click on the blue button to read which complications
you may suffer from due to the operation
41
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Back
Death from surgery:
Figure 3 Various graphical presentations provided of the probabilities of beneﬁ  t and harm involved in surgical AAA treatment to suit patient preferences, in clockwise order: 
natural frequency trees, bars, percentages, and visual aids.
Figure 4 Sample page from the decision aid concerning the comparison of surgery versus watchful observation and assessment of the patients’ individual opinion about their 
anxiety and considerations.
Benefit
o After surgery, the chance of rupture of the 
aneurysm and subsequent death become very
unlikely
o Your surgeon anticipates you will live longer
because of the operation
Harm
o You will run the risk of dying or (serious) 
complications due to the operation
o Although your surgeon anticipates you will live 
longer after the operation, it is not exactly
known how much longer.
o After surgery you will need a recovery period
of about 3  to 6 months to return to normal 
life. If you undergo the operation via the 
groin, the recovery period is shorter (about 1 
to 3 months). 
Benefit
o You will avoid the risk of dying or (serious) 
complications due to the operation
o You do not have to recover from an operation. 
This would require a recovery period of about
3  to 6 months to return to normal life. If you 
were to undergo the operation via the groin, 
the recovery period would be shorter (about 1  
to 3 months). 
Harm
o You still run the risk of a rupture of the 
aneurysm and of dying from it. This may
frighten you and your relatives.
o You must visit your surgeon once a year to 
check the growth of the aneurysm. 
Endovascular surgery Watchful observation
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At this point you have been informed about: 
o The aneurysm of the abdominal aorta and the possible treatment options. 
o Your personal risk of a rupture of the aneurysm (from which most people die).
o Your personal risk of dying or suffering (serious) complications due to the operation.
o Important things to consider before you can make your decision 
It is now up to you, and your surgeon and relatives, to decide which considerations are deciding.
Continue
You have now seen the possible harms and benefits of each treatment option. 
What is your opinion about the following statements? Check the appropriate box.
I am anxious or worried if I do not get surgical treatment
I could live with a (serious) complication due to the operation
Yes, a lot             Yes, somewhat Not sure No, not really  No, not at all 
Fully agree Agree Not sure Disagree Fully disagree
44
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Table 1 Characteristics of 15 patients who tested the pilot version 
of the decision aid
Male gender 12 out of 15 (80%)
Age (mean; range) 71 (62–78 yrs)
AAA since (years; range) 6 (2–13 yrs)
AAA diameter (cm; range) 4.8 (3.3–7.5 cm)
Operated? (open or endovascular) 40% (Half of them open surgery)
Computer (+ internet) user 73%
Abbreviation: AAA, abdominal aorta aneurysm.
Fifteen patients evaluated the pilot version of the DA. 
Patient characteristics are shown in Table 1. They examined 
the DA for a mean of 80 minutes (range 20–300 min.). On a 
scale from zero to 100, ‘user-friendliness’ scored a median of 
75 (interquartile range [IQR] 53–86), ’understandability’ 86 
(IQR 80–90), and ‘feeling better informed’ 68 (IQR 50–90). 
The vast majority of patients stated the DA offered additional 
value in their decision making, and all but one patient found 
the ﬁ  gures on possible risks clarifying rather than frighten-
ing. Every type of graphical representation was valued most 
by at least some of the patients. No clear differences were 
observed between patients who had and those who had not 
yet undergone surgical treatment for their AAA.
Finally, a linguistic check was performed (SM) to ensure 
the use of plain language and easy interpretation of the DA. 
The program, now available on CDROM, was also equipped 
with the possibility to print concise information in the form 
of a brochure the patient can take home. The DA has been 
registered in the Cochrane Decision Aid Library Inventory 
(DALI) of the Ottawa Health Decision Centre (see https://
decisionaid.ohri.ca/DALI).
Discussion
In this paper the development of the ﬁ  rst DA regarding 
treatment options for patients with an asymptomatic AAA 
is described. This computer-based DA is evidence-based, is 
developed according to the IPDAS criteria, and is approved 
by the Dutch Society of Vascular Patients.
The development of this DA was similar to those in 
other medical realms, eg, cancer of the breast, prostate, or 
lungs (Molenaar et al 2001; Feldman-Stewart and Brundage 
2004; Holmes-Rovner 2005; Chiew et al 2007), in which 
patients may be overwhelmed by a potentially life-threaten-
ing diagnosis and at the same time are invited to participate 
in treatment decision making. On the other hand, this DA 
differs in that it focuses on an asymptomatic disorder that will 
remain without consequences until either rupture or surgical 
treatment occurs. In addition, this DA may offer surgeons 
a tool to share necessary information in an evidence-based, 
standardized format.
In only one RCT the beneﬁ  ts of a comprehensive, highly 
individualized, evidence-based brochure for asymptomatic 
AAA patients based on information by way of Markov 
analysis have been studied. The highly individualized 
information was found to be dissatisfying and impractical 
(Molewijk 2006). Therefore, the information offered in this 
DA was mainly on headlines rather than focusing only on 
the individual situation of each patient (Feldman-Stewart 
and Brundage 2004). However, as risk of rupture strongly 
correlates to the size of the aneurysm, and surgical risk 
considerably increases with the presence of comorbidity, 
it was thought to be necessary to tailor information in the 
DA to these two factors in order for the DA to be a useful 
adjuvant in the communication between patient and surgeon. 
In addition, the IPDAS criteria also describe “the possibility 
to view probabilities based on the patient’s own situation” 
as one of the quality criteria.
This DA was made in accordance with the vast majority 
of IPDAS criteria. Although these criteria are not yet com-
monly applied, they should improve the value of DAs to let 
patients better understand their own condition, to reduce 
decisional conﬂ  ict, and to help them make an informed choice 
(O’Connor et al 2007). The debate is ongoing about the value 
of DAs to improve clinical decision making (Holmes-Rovner 
et al 2007). DAs did not appear to outperform comparative 
strategies in affecting patient satisfaction with decision mak-
ing, anxiety, and health outcomes (O’Connor et al 2003). 
Furthermore, DAs can only be developed if evidence is 
available in sufﬁ  cient amounts to underpin the information 
supplied for the various treatment alternatives.
The initial version of this decision support had limitations 
as to the complexity of the individual risk information, which 
was dissatisfying for the patient. After adjustments, appraisal 
by AAA patients showed that this DA was considered user-
friendly, of additional value, and improved understanding. 
As intended, the DA was found to be not simply an informa-
tive ‘digital brochure’ containing basic information about 
treatment options, but rather seemed to be a possibly useful 
tool to actually help patients decide upon their optimum 
treatment choice.
We actually do not yet know whether the DA really offers 
more (useful) information than what the vascular surgeons 
already explain to the patient and whether it is also capable 
of increasing patients’ knowledge and subsequently reducing 
patients’ decisional conﬂ  ict regarding their treatment choice. 
Ultimately, it might also improve satisfaction, quality of life, Patient Preference and Adherence 2008:2 321
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Table 2 Patient questionnaire about their appreciation of the decision aid.   The ﬁ  rst three questions are based on visual analogue scales
1.  How much time did you spend examining the decision aid?
 …  hrs  …  mins
2. Did  you  ﬁ  nd the decision aid user friendly?
   User  friendly  Not user friendly
3. Did  you  ﬁ  nd the information in the decision aid understandable?
   Understandable  Not understandable
4. Would you have felt better informed if you had seen this decision aid before a decision about your treatment was made?
   Y e s No
5. When choosing which information you want to see, do you prefer a digital decision aid over a paper-based one?
   Y e s No
6.  Do you think the decision aid can help patients (who visit their surgeon for the ﬁ  rst time for their aneurysm) choose between the treatment options?
     Yes
      No
7.  Did you the ﬁ  nd the ﬁ  gures about surgical risks frightening or clarifying?
     Frightening
      Clarifying
and prevent a relevant increase in anxiety of asymptomatic 
AAA patients. Moreover, it might possibly affect the number 
of AAA interventions eventually performed. This is being 
studied in an ongoing trial on the usefulness of this DA in a 
randomized setting.
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